Advertisement
U.S. markets open in 7 hours 16 minutes
Advertisement

AstraZeneca PLC (AZN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
63.51-0.08 (-0.13%)
At close: 04:00PM EST
63.68 +0.17 (+0.27%)
After hours: 07:55PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close63.59
Open63.82
Bid0.00 x 1200
Ask0.00 x 2900
Day's Range63.07 - 63.82
52 Week Range61.73 - 76.56
Volume6,027,572
Avg. Volume5,539,653
Market Cap197.751B
Beta (5Y Monthly)0.17
PE Ratio (TTM)33.60
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.45 (2.28%)
Ex-Dividend DateAug 10, 2023
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
38% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for AZN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Astrazeneca PLC
    Weekly Stock ListGlobal stocks are picking up the pace. While the S&P 500 has jumped almost 11% in the past month, the EAFA index of large- and mid-cap stocks based in countries other than the U.S. and Canada has risen 10%. Over the past six years, the performance gap has been wider, with the S&P 500 advancing 12% compared to a 7% gain for the EAFE. But the underperformance has given global stocks a valuation advantage, particularly in the area of dividends. The EAFE dividend yield of 2.4% is 80 basis points higher than the comparable S&P 500 dividend yield. We think global dividend stocks now offer opportunity, particularly given the endless speculation over the direction of interest rates in the U.S., which has created market-timing headaches for equity income investors. Those investors have endured recent wide swings in prices for rate-sensitive equity sectors such as Utilities, REITs and MLPs. In our view, investing in international income stocks is one way to increase portfolio diversification while reducing sensitivity to volatile U.S interest rates. Investing in overseas stocks carries its own set of risks, including the impact of currency exchange and geopolitical turmoil. But there are also a number of positives in this asset class for U.S. investors, including a wide selection of companies that pay dividends, robust industry diversification, and, as we have mentioned, higher yields and lower valuations. Argus has recently boosted its global coverage, and recommends the following international dividend stocks, each of which has at least a long-term HOLD rating from an Argus analyst.
    Rating
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • Yahoo Finance Video

    FTC warns pharma companies on excessive drug patenting

    The Federal Trade Commission (FTC) issued warning letters to several pharmaceutical companies, including AbbVie (ABBV) AstraZeneca (AZN), and Teva (TEVA), over excessive patenting of medications as Medicare negotiates drug costs with the pharma industry. Yahoo Finance Health Reporter Anjalee Khemlani explains the Biden administration's ideas to license patents to lower drug costs for patients. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.

  • Reuters

    UPDATE 2-US urges makers of infant RSV shots to meet winter demand

    U.S. officials met with manufacturers of the infant and toddler RSV immunization Beyfortus this week seeking to boost access to the shot, the White House said in a statement on Thursday after senior Biden administration officials met with the companies last week. The officials on Tuesday met with representatives of Sanofi , AstraZeneca and Thermo Fisher "and urged them to work expeditiously to meet demand for immunizations this winter season through the commercial market," the White House said in a statement.

  • Zacks

    AstraZeneca PLC (AZN) Is a Trending Stock: Facts to Know Before Betting on It

    Zacks.com users have recently been watching Astrazeneca (AZN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.